Age-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2019 Aug 17

PMID 31417399

Citations 33

Authors

Franciska Erdo

Peter Krajcsi

Affiliations

Soon will be listed here.

Abstract

During the last decade, several articles have reported a relationship between advanced age and changes in the integrity of the blood-brain barrier (BBB). These changes were manifested not only in the morphology and structure of the cerebral microvessels but also in the expression and function of the transporter proteins in the luminal and basolateral surfaces of the capillary endothelial cells. Age-associated downregulation of the efflux pumps ATP-binding cassette transporters (ABC transporters) resulted in increased permeability and greater brain exposure to different xenobiotics and their possible toxicity. In age-related neurodegenerative pathologies like Alzheimer's disease (AD), the amyloid-β (Aβ) clearance decreased due to P-glycoprotein (P-gp) dysfunction, leading to higher brain exposure. In stroke, however, an enhanced P-gp function was reported in the cerebral capillaries, making it even more difficult to perform effective neuroprotective therapy in the infarcted brain area. This mini-review article focuses on the efflux functions of the transporters and receptors of the BBB in age-related brain pathologies and also in healthy aging.

Citing Articles

Endothelial-Ercc1 DNA repair deficiency provokes blood-brain barrier dysfunction.

Hansen C, Vacondio D, van der Molen L, Juttner A, Fung W, Karsten M Cell Death Dis. 2025; 16(1):1.

PMID: 39753531 PMC: 11698980. DOI: 10.1038/s41419-024-07306-0.

The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications.

Banks W, Rhea E, Reed M, Erickson M Cell Rep Med. 2024; 5(11):101760.

PMID: 39383873 PMC: 11604479. DOI: 10.1016/j.xcrm.2024.101760.

Proteomic Profiling Reveals Age-Related Changes in Transporter Proteins in the Human Blood-Brain Barrier.

Zhou X, Azimi M, Handin N, Riselli A, Vora B, Chun E bioRxiv. 2024; .

PMID: 39091855 PMC: 11291171. DOI: 10.1101/2024.07.26.604313.

Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems.

Loeffler D J Alzheimers Dis. 2024; 100(2):379-411.

PMID: 38875041 PMC: 11307100. DOI: 10.3233/JAD-240212.

Enhancing of cerebral Abeta clearance by modulation of ABC transporter expression: a review of experimental approaches.

Loeffler D Front Aging Neurosci. 2024; 16:1368200.

PMID: 38872626 PMC: 11170721. DOI: 10.3389/fnagi.2024.1368200.

References

Shibata M, Yamada S, Kumar S, Calero M, Bading J, Frangione B . Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000; 106(12):1489-99. PMC: 387254. DOI: 10.1172/JCI10498. View

Banks W, Farr S, Morley J . Permeability of the blood-brain barrier to albumin and insulin in the young and aged SAMP8 mouse. J Gerontol A Biol Sci Med Sci. 2000; 55(12):B601-6. DOI: 10.1093/gerona/55.12.b601. View

Rosati A, Maniori S, Decorti G, Candussio L, Giraldi T, Bartoli F . Physiological regulation of P-glycoprotein, MRP1, MRP2 and cytochrome P450 3A2 during rat ontogeny. Dev Growth Differ. 2003; 45(4):377-87. DOI: 10.1046/j.1440-169x.2003.00699.x. View

Zhang Y, Schuetz J, Elmquist W, Miller D . Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther. 2004; 311(2):449-55. DOI: 10.1124/jpet.104.068528. View

Ueno M, Akiguchi I, Yagi H, Naiki H, Fujibayashi Y, Kimura J . Age-related changes in barrier function in mouse brain I. Accelerated age-related increase of brain transfer of serum albumin in accelerated senescence prone SAM-P/8 mice with deficits in learning and memory. Arch Gerontol Geriatr. 1993; 16(3):233-48. DOI: 10.1016/0167-4943(93)90035-g. View

Nies A, Jedlitschky G, Konig J, Herold-Mende C, Steiner H, Schmitt H . Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience. 2004; 129(2):349-60. DOI: 10.1016/j.neuroscience.2004.07.051. View

Sasongko L, Link J, Muzi M, Mankoff D, Yang X, Collier A . Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther. 2005; 77(6):503-14. DOI: 10.1016/j.clpt.2005.01.022. View

Vogelgesang S, Warzok R, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer H . The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res. 2005; 1(2):121-5. PMC: 2763541. DOI: 10.2174/1567205043332225. View

Toornvliet R, van Berckel B, Luurtsema G, Lubberink M, Geldof A, Bosch T . Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006; 79(6):540-8. DOI: 10.1016/j.clpt.2006.02.004. View

10.

Ohtsuki S, Kamoi M, Watanabe Y, Suzuki H, Hori S, Terasaki T . Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor. Biol Pharm Bull. 2007; 30(6):1144-6. DOI: 10.1248/bpb.30.1144. View

11.

Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I . MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol. 2007; 17(4):347-53. PMC: 8095502. DOI: 10.1111/j.1750-3639.2007.00075.x. View

12.

Pelegri C, Canudas A, Del Valle J, Casadesus G, Smith M, Camins A . Increased permeability of blood-brain barrier on the hippocampus of a murine model of senescence. Mech Ageing Dev. 2007; 128(9):522-8. DOI: 10.1016/j.mad.2007.07.002. View

13.

Ravenstijn P, Merlini M, Hameetman M, Murray T, Ward M, Lewis H . The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments. J Pharmacol Toxicol Methods. 2007; 57(2):114-30. DOI: 10.1016/j.vascn.2007.10.003. View

14.

Bartels A, Willemsen A, Kortekaas R, de Jong B, de Vries R, de Klerk O . Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm (Vienna). 2008; 115(7):1001-9. PMC: 2468317. DOI: 10.1007/s00702-008-0030-y. View

15.

Bartels A, van Berckel B, Lubberink M, Luurtsema G, Lammertsma A, Leenders K . Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism Relat Disord. 2008; 14(6):505-8. DOI: 10.1016/j.parkreldis.2007.11.007. View

16.

Bartels A, Kortekaas R, Bart J, Willemsen A, De Klerk O, de Vries J . Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging. 2008; 30(11):1818-24. DOI: 10.1016/j.neurobiolaging.2008.02.002. View

17.

Roberts L, Black D, Raman C, Woodford K, Zhou M, Haggerty J . Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation. Neuroscience. 2008; 155(2):423-38. DOI: 10.1016/j.neuroscience.2008.06.015. View

18.

Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M . Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic.... Drug Metab Dispos. 2008; 37(2):315-21. DOI: 10.1124/dmd.108.024018. View

19.

Bell R, Zlokovic B . Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 2009; 118(1):103-13. PMC: 2853006. DOI: 10.1007/s00401-009-0522-3. View

20.

Poller B, Drewe J, Krahenbuhl S, Huwyler J, Gutmann H . Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol. 2009; 30(1):63-70. PMC: 11498628. DOI: 10.1007/s10571-009-9431-1. View